ClinicalTrials.gg
RecruitingNCT06447064(CLOCS-2)Updated Mar 25, 2026

Cancer Loyalty Card Study 2 (CLOCS-2)

An observational study in Pancreatic Cancer, Colon Cancer and Oesophageal Cancer, sponsored by Imperial College London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Imperial College London · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
2,900
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 177 studies in Pancreatic Neoplasms with a site in United Kingdom — 42 open to participants now, 57 under way, 11 of them phase 3. Pancreatic Neoplasms · United Kingdom.

Planned enrollment
7th of 38
2,900 · median 215
Started
2026
with 9 others
Observational
38 of 177
14 open now
Primary completion
2027-02
later than 18 of 56 live
Registered
154th of 177
by date
Lead sponsor
5 of 177
Imperial College London

Among the 177 studies in Pancreatic Neoplasms with a site in United Kingdom, this one is the 7th largest by planned enrollment of the 38 observational ones that give a count, is one of 10 that started in 2026, is one of 38 observational ones, reaches primary completion later than 18 of the 56 other live ones, and was the 154th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

42 of the 177 studies in Pancreatic Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

36 more — sign in →

All 42 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 177 studies in Pancreatic Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

Cancer is one of the leading causes of mortality worldwide and is responsible for an estimated 9.6 million deaths yearly. Cancer-related deaths can be reduced if patients are diagnosed and treated early. Delay in cancer diagnosis can occur at any point along the diagnostic spectrum, from the first observation of symptoms to the start of treatment. Diagnosing cancer when it is still at an early stage, before it has spread, gives surgery, radiotherapy and other treatments the best chance of working.

Therefore, early diagnosis is the most important way to improve cancer outcomes.Most of the cancers usually presents with vague and non-alarming symptoms. Most individuals are diagnosed late when the cancer has already spread, and the prognosis is poor. There are over 200 different types of cancer that can cause many different signs and symptoms. Sometimes symptoms affect specific body areas, such as abdomen or skin. But signs can also be more general, and include weight loss, tiredness (fatigue) or unexplained pain. The type of symptoms varies from person to person.

The major reasons for not presenting to the GP with symptoms such as these are "not wanting to waste the GP's time" and normalisation of these symptoms.

The persistence of a symptom, social influence and awareness encourage help-seeking behaviours in primary care. However, few believe their symptom(s) might be a sign of cancer. Consequently, people might choose to self-manage their symptoms by using over-the-counter medication, and to seek advice from other sources, (pharmacists, family, internet), rather than a primary care physician.

RATIONALE FOR CURRENT STUDY

An early cancer diagnosis is essential for receiving treatment as early as possible to have the best chance for successful treatment. Early diagnosis of cancer can be challenging. Sometimes, the cancer symptoms resemble common illnesses and could resolve with the use of over-the-counter medications and other remedies until they become persistent or debilitating. The present study focuses on ten cancer forms: colon, oesophageal, stomach, liver, bladder, uterine, vulval, ovarian, endometrial and pancreatic. Patients diagnosed with the cancers mentioned above often report experiencing vague symptoms (such as abdominal or back pain, indigestion, feeling full etc). They often use over-the-counter medication to manage their symptoms before seeing a doctor.

Information about how often and what products participants purchase (e.g. pain killers, digestive products and natural remedies) to care for these symptoms could help identify these cancers a few crucial weeks or months earlier and encourage people to seek help sooner from their doctors.

Read the detailed description

Purpose and Design

The Cancer Loyalty Card Study-2 (CLOCS-2) addresses whether or not data already collected by high street retailers can detect significant changes in cancer patients' purchase behaviours before their diagnosis. The aim is to conduct a case-control study of cancer patients matched with participants without these cancer types. 1450 recently diagnosed cancer patients and 1450 participants as controls will be recruited and up to six years of prior purchase data will be collated.

Recruitment

Participants, 18 years or older, with any of the aforementioned cancer forms and having at least one of the participating high street retailer's loyalty cards from Tesco or Boots in their household, will be recruited through the GP invites, NHS cancer clinics and Be Part of Research.

All participants registering in the study and not holding the primary ownership of the loyalty cards from Tesco or Boots must register in the study along with the primary owner of the loyalty card from the same household. All the collected data will be safeguarded in a secure enclave with limited access to the CLOCS-2 team.

Consent

All participants will be given the information sheet and consent form through a REDCap link shared through messages sent by GP, cancer clinics or Be Part of Research. They can take as much time as they need to read through the information sheet. If they choose to participate, they can complete the consent form whenever convenient and fill it out online at REDCap.

Methods

Loyalty card holders with primary ownership of at least one of the participating high street retailers loyalty cards from Tesco or Boots and their family members living in the same household are eligible to participate in CLOCS-2. All participants will be invited to join the study by invites (sent through text messages from GP, cancer clinics or Be Part of Research) and can choose to sign up via a link provided in invites that leads to REDCap. People over 18 years of age and with any form of cancer as listed earlier and who use at least one of the participating high street retailer's loyalty cards in their household will be recruited as cases. Whereas people over 18 years of age, without the diagnosis of these cancer types and using at least one of the participating high street retailer's loyalty cards in their households will be recruited as control participants.

Consenting participants will complete a brief online questionnaire at REDCap about their health, clinical history and lifestyle choices. To adhere to participating high street retailers' policies, only participants whose details cannot be matched to that of the retailers' will need to provide a photo ID and utility bill for ID verification.

The tentative participant recruitment date is 01/11/2025. Once the participants are recruited in the study, their past six years of purchase history will be requested from Tesco/Boots from the recruitment date. This data received from these high street retailers will be non-identifiable pseudonymised data. Participant identity will be linked to the analysis datasets only through a unique barcode assigned when completing the recruitment questionnaire, meaning the data will be pseudonymised. The only identifiable information will be on the consent form and the participant barcode. Retailer and questionnaire data will only be linked via the pseudonymised participant barcode.

If participants consent to be re-contacted by the CLOCS-2 team for future studies or loyalty card detail clarification, they can opt for it in their consent forms. No further action is needed from participants once they complete their consent form and questionnaire (and clarify loyalty card details if necessary). Participants will be provided with the study's website and encouraged to visit the study's website for updates.

03

Conditions studied

  • Pancreatic Cancer
  • Colon Cancer
  • Oesophageal Cancer
  • Stomach Cancer
  • Liver Cancer
  • Bladder Cancer
  • Uterine Cancer
  • Vulvar Cancer
  • Ovarian Cancer
  • Endometrial Cancer

Keywords

  • Ovarian Cancer
  • Epidemiology
  • Observational Study
  • Risk Assessment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Adults aged ≥18 years old, who own at least one participating high street retailer loyalty cad in their household. Among these individuals, those who have been diagnosed with any form of cancer as mentioned above (can join the CLOCS-2 as cases, and those who have no prior cancer diagnosis from the list of cancers mentioned above are eligible to join as controls.

Eligibility criteria

Inclusion Criteria (ALL):

  • Individuals aged >18 years of age
  • Individuals must be residing in the United Kingdom at the time of giving
  • Individuals must be registered with an NHS GP Practice
  • Individuals must meet the criteria of ONE of the groups. For example, to be eligible for Group 1 (Cases), individuals must have been diagnosed with one of the following cancer types in the last 24 months: Bladder, colorectal (bowel), endometrial, liver, oesophageal, ovarian, pancreatic, stomach (gastric), uterine, or vulval; whereas for Group 2 (Controls), individuals must not have received a cancer diagnosis of any type in the last 6 years (except where the diagnosis was of non-melanoma skin cancer).
  • Individuals must be a primary registered cardholder* of one of the loyalty cards listed below, and consent to share their loyalty card data with the study team
  • Tesco Clubcard
  • Boots Advantage Card
  • Provision of written informed consent
  • Willing and able to comply with all required study activities

    • The primary registered card holder, i.e., the person who is named on the loyalty card account, must also enrol into the study, if someone other than the registered primary card holder from the same household, wants to take part in the study.

Exclusion Criteria (ALL):

  • Individuals under the age of 18 years
  • Non-UK residents, at the time of giving informed consent
  • Individuals without an eligible loyalty card, or who have no one in their household who has an eligible loyalty card
  • Individuals who are not the primary registered cardholder in their household and where the primary registered loyalty card holder is not willing to join the study, and/or where the primary registered cardholder does not make purchases for or on behalf of the individual

Exclusion Criteria (CASES):

  • Individuals will not be able to join as a case if:
  • they have been diagnosed with an eligible cancer type more than 24 months ago (except where the diagnosis was non-melanoma skin cancer).
  • they have received an ineligible cancer diagnosis within the last 6 years except where the diagnosis was non-melanoma skin cancer).

Exclusion Criteria (Controls):

  • Individuals will not be able to join as a control (Group 2) if:

o they have received any cancer diagnosis in the last six years (except where the diagnosis was non-melanoma skin cancer).

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
2,900 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cases

    Participants diagnosed with cancer.

    Other: Cases & Controls

  • Controls

    Participants not diagnosed with cancer.

    Other: Cases & Controls

Interventions

  • OtherCases & Controls

    Participants will complete a brief online questionnaire at REDCap about their health, clinical history and lifestyle choices. The participant will only need to provide a photo ID and utility bill for ID verification, if the retailer cannot match participant details. After recruitment the participants purchase history in the past 6 years will be requested from the retailers.

06

What researchers measure

Primary outcomes

  1. Purchase behaviours (purchase of pain relief medications) assessed by Statistical Model

    The primary outcome of the CLOCS-2 will be to define the time by which the cases and controls are statistically significantly (p≤0.05) different in their purchase behaviours leading up to a cancer diagnosis on a population level.

    Time frame: 3 years

Secondary outcomes

  1. Alert about Cancer symptoms assessed by purchase behaviour

    Defining a purchase threshold as an 'alert' about cancer symptoms in individuals and determining the predictive utility of purchasing behaviours in the early detection of these cancer forms.

    Time frame: 3 years

  2. Development of risk profiles for each cancer type

    Risk profiles for each main cancer type created from the participants self-reported health data; adjusted for in the analyses

    Time frame: 3 years

  3. Development of predictive model to assess utility of purchasing behaviours

    A predictive model to assess the utility of identified purchasing behaviours in early cancer detection, tested for efficacy of its predictive utility of purchasing behaviours in the early detection of these cancer forms

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Toopchiani S, Codling S, Pondeca Y, Kaur S, Horeau K, Brewer H, Cross A, Delaney B, Faisal AA, Peters C, Goulding J, Hirst Y, Sundar S, Flanagan JM. Cancer loyalty card study-2 (CLOCS-2): protocol for an observational case-control study focusing on the patient interval in cancer diagnosis. BMJ Open. 2026 May 13;16(5):e117937. doi: 10.1136/bmjopen-2026-117937. PubMed 42128509 ↗

Individual participant data

Plan to share: No — Only aggregated and anonymised survey data will be shared with other researchers after publication. No sensitive individual level data will be shared.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2024
First posted
Jun 6, 2024
StartActual
Feb 4, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Apr 2027
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06447064
Collaborators
University of Birmingham, University of Nottingham, University of Central Lancashire, Cancer Research UK, Imperial College Healthcare NHS Trust
Responsible party
Sponsor
First posted
Jun 6, 2024
Start date
Feb 4, 2026
Primary completion
Feb 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Mar 25, 2026

Study contacts

Yuscah Pondeca
Contact
yuscah.pondeca16@imperial.ac.uk
02075942127
Dr James Flanagan
Contact
j.flanagan@imperial.ac.uk
02075942127
Dr James Flanagan
principal investigator · Imperial College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion